Plain-English translation of NCT03463252 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether Levonorgestrel-Releasing Intrauterine System (a small hormone-releasing device placed in the uterus) can effectively treat early-stage womb cancer and precancerous changes of the uterus in younger women who want to preserve their ability to have children. The study will compare using this device alone, a hormone pill alone, or a combination of both. Researchers will track how well the treatment works and whether patients are able to become pregnant afterward.
Womb cancer is usually treated by removing the uterus, which ends a woman's ability to have biological children. This trial exists to find out if this medication can be an alternative option for younger women diagnosed with early-stage disease who want to keep their fertility.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will be randomly assigned to one of three groups: hormone pill alone, the intrauterine device alone, or a combination of both. You will receive continuous treatment for 3 months, followed by a uterine biopsy and examination with a small camera to check how well the treatment is working. Depending on your response, you may continue treatment for up to 3 cycles total. Throughout the study, you will have regular office visits to monitor your progress and side effects. If the treatment is successful, your doctors will help you plan for pregnancy.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
China